BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Allimant C, Kafrouni M, Delicque J, Ilonca D, Cassinotto C, Assenat E, Ursic-bedoya J, Pageaux G, Mariano-goulart D, Aho S, Guiu B. Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. Journal of Vascular and Interventional Radiology 2018;29:1662-1670.e4. [DOI: 10.1016/j.jvir.2018.07.006] [Cited by in Crossref: 22] [Cited by in F6Publishing: 17] [Article Influence: 5.5] [Reference Citation Analysis]
Number Citing Articles
1 Plachouris D, Tzolas I, Gatos I, Papadimitroulas P, Spyridonidis T, Apostolopoulos D, Papathanasiou N, Visvikis D, Plachouri KM, Hazle JD, Kagadis GC. A deep-learning-based prediction model for the biodistribution of 90 Y microspheres in liver radioembolization. Med Phys 2021;48:7427-38. [PMID: 34628667 DOI: 10.1002/mp.15270] [Reference Citation Analysis]
2 Son MH, Ha LN, Bang MH, Bae S, Giang DT, Thinh NT, Paeng JC. Diagnostic and prognostic value of 99mTc-MAA SPECT/CT for treatment planning of 90Y-resin microsphere radioembolization for hepatocellular carcinoma: comparison with planar image. Sci Rep 2021;11:3207. [PMID: 33547398 DOI: 10.1038/s41598-021-82887-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
3 Mahvash A, Chartier S, Turco M, Habib P, Griffith S, Brown S, Kappadath SC. A prospective, multicenter, open-label, single-arm clinical trial design to evaluate the safety and efficacy of 90Y resin microspheres for the treatment of unresectable HCC: the DOORwaY90 (Duration Of Objective Response with arterial Ytrrium-90) study. BMC Gastroenterol 2022;22. [DOI: 10.1186/s12876-022-02204-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Sharma NK, Kappadath SC, Chuong M, Folkert M, Gibbs P, Jabbour SK, Jeyarajah DR, Kennedy A, Liu D, Meyer JE, Mikell J, Patel RS, Yang G, Mourtada F. The American Brachytherapy Society consensus statement for permanent implant brachytherapy using Yttrium-90 microsphere radioembolization for liver tumors. Brachytherapy 2022. [DOI: 10.1016/j.brachy.2022.04.004] [Reference Citation Analysis]
5 d’Abadie P, Walrand S, Lhommel R, Hesse M, Borbath I, Jamar F. Optimization of the Clinical Effectiveness of Radioembolization in Hepatocellular Carcinoma with Dosimetry and Patient-Selection Criteria. Current Oncology 2022;29:2422-34. [DOI: 10.3390/curroncol29040196] [Reference Citation Analysis]
6 Elsayed M, Loya M, Galt J, Schuster DM, Bercu ZL, Newsome J, Brandon D, Benenati S, Behbahani K, Duszak R, Sethi I, Kokabi N. Same day yttrium-90 radioembolization with single photon emission computed tomography/computed tomography: An opportunity to improve care during the COVID-19 pandemic and beyond. World J Gastrointest Oncol 2021; 13(5): 440-452 [PMID: 34040704 DOI: 10.4251/wjgo.v13.i5.440] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Rodríguez-Fraile M, Ezponda A, Grisanti F, Morán V, Calvo M, Berián P, de la Cuesta AM, Sancho L, Iñarrairaegui M, Sangro B, Bilbao JI. The joint use of 99mTc-MAA-SPECT/CT and cone-beam CT optimizes radioembolization planning. EJNMMI Res 2021;11:23. [PMID: 33661428 DOI: 10.1186/s13550-021-00764-z] [Reference Citation Analysis]
8 Mikell JK, Dewaraja YK, Owen D. Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models. Semin Radiat Oncol 2020;30:68-76. [PMID: 31727302 DOI: 10.1016/j.semradonc.2019.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
9 Saini A, Wallace A, Alzubaidi S, Knuttinen MG, Naidu S, Sheth R, Albadawi H, Oklu R. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma. J Clin Med 2019;8:E55. [PMID: 30621040 DOI: 10.3390/jcm8010055] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 9.0] [Reference Citation Analysis]
10 Ghosn M, Derbel H, Kharrat R, Oubaya N, Mulé S, Chalaye J, Regnault H, Amaddeo G, Itti E, Luciani A, Kobeiter H, Tacher V. Prediction of overall survival in patients with hepatocellular carcinoma treated with Y-90 radioembolization by imaging response criteria. Diagn Interv Imaging 2021;102:35-44. [PMID: 33012693 DOI: 10.1016/j.diii.2020.09.004] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
11 Sarwar A, Ali A, Ljuboja D, Weinstein JL, Shenoy-Bhangle AS, Nasser IA, Morrow MK, Faintuch S, Curry MP, Bullock AJ, Ahmed M. Neoadjuvant Yttrium-90 Transarterial Radioembolization with Resin Microspheres Prescribed Using the Medical Internal Radiation Dose Model for Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol 2021;32:1560-8. [PMID: 34454031 DOI: 10.1016/j.jvir.2021.08.009] [Reference Citation Analysis]
12 Hesse M, d'Abadie P, Lhommel R, Jamar F, Walrand S. Yttrium-90 TOF-PET-Based EUD Predicts Response Post Liver Radioembolizations Using Recommended Manufacturer FDG Reconstruction Parameters. Front Oncol 2021;11:592529. [PMID: 34676157 DOI: 10.3389/fonc.2021.592529] [Reference Citation Analysis]
13 Piron L, Cassinotto C, Guiu B. [Interventional radiology of liver tumors]. Presse Med 2019;48:1156-68. [PMID: 31672452 DOI: 10.1016/j.lpm.2019.10.010] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Stephan W, Michel H. PET/CT Specificities in 90Y Imaging Post Radioembolization. PET Clinics 2019;14:469-76. [DOI: 10.1016/j.cpet.2019.06.001] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Chiesa C, Bardiès M, Zaidi H. Voxel‐based dosimetry is superior to mean absorbed dose approach for establishing dose‐effect relationship in targeted radionuclide therapy. Med Phys 2019;46:5403-6. [DOI: 10.1002/mp.13851] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
16 Lakhoo J, Perez TH, Borgmann AJ, Brown DB. Lobar Radioembolization for Intermediate and Advanced Hepatocellular Carcinoma: Retrospective and Prospective Data. Semin Intervent Radiol 2021;38:412-8. [PMID: 34629707 DOI: 10.1055/s-0041-1733903] [Reference Citation Analysis]
17 Plachouris D, Mountris KA, Papadimitroulas P, Spyridonidis T, Katsanos K, Apostolopoulos D, Papathanasiou N, Hazle JD, Visvikis D, Kagadis GC. Clinical Evaluation of a Three-Dimensional Internal Dosimetry Technique for Liver Radioembolization with 90Y Microspheres Using Dose Voxel Kernels. Cancer Biother Radiopharm 2021. [PMID: 33656372 DOI: 10.1089/cbr.2020.4554] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Graves SA, Hobbs RF. Dosimetry for Optimized, Personalized Radiopharmaceutical Therapy. Semin Radiat Oncol 2021;31:37-44. [PMID: 33246635 DOI: 10.1016/j.semradonc.2020.07.008] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Garin E, Palard X, Rolland Y. Personalised Dosimetry in Radioembolisation for HCC: Impact on Clinical Outcome and on Trial Design. Cancers (Basel) 2020;12:E1557. [PMID: 32545572 DOI: 10.3390/cancers12061557] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
20 Kurilova I, Bendet A, Fung EK, Petre EN, Humm JL, Boas FE, Crane CH, Kemeny N, Kingham TP, Cercek A, D'Angelica MI, Beets-Tan RGH, Sofocleous CT. Radiation segmentectomy of hepatic metastases with Y-90 glass microspheres. Abdom Radiol (NY) 2021;46:3428-36. [PMID: 33606062 DOI: 10.1007/s00261-021-02956-6] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 7.0] [Reference Citation Analysis]
21 Gulec SA, Mcgoron AJ. Radiomicrosphere Dosimetry: Principles and Current State of the Art. Seminars in Nuclear Medicine 2022. [DOI: 10.1053/j.semnuclmed.2021.12.009] [Reference Citation Analysis]
22 Reeves HL, Reicher J, Priona G, Manas DM, Littler P. Selective internal radiation therapy (SIRT) for hepatocellular carcinoma (HCC): informing clinical practice for multidisciplinary teams in England. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2022-102137] [Reference Citation Analysis]
23 Guiu B, Garin E, Allimant C, Edeline J, Salem R. TARE in Hepatocellular Carcinoma: From the Right to the Left of BCLC. Cardiovasc Intervent Radiol 2022. [PMID: 35149884 DOI: 10.1007/s00270-022-03072-8] [Reference Citation Analysis]
24 Kwee SA, Wong LL, Sato MM, Acoba JD, Rho YS, Srivastava A, Landsittel DP. Transarterial Radioembolization for Hepatocellular Carcinoma with Major Vascular Invasion: A Nationwide Propensity Score-Matched Analysis with Target Trial Emulation. J Vasc Interv Radiol 2021;32:1258-1266.e6. [PMID: 34242775 DOI: 10.1016/j.jvir.2021.07.001] [Reference Citation Analysis]
25 Cheng B, Sethi I, Villalobos A, Wagstaff W, Schuster DM, Bercu Z, Brandon D, Kokabi N. Determination of tumour dose response threshold and implication on survival in patients with HCC treated with Y90 radiation segmentectomy: a simple semi-quantitative analysis. Nucl Med Commun 2021;42:892-8. [PMID: 33795611 DOI: 10.1097/MNM.0000000000001420] [Reference Citation Analysis]
26 Walrand S, Chiesa C, Gabina PM, Chouin N, Gear J, Stokke C, Bernhardt P, Gleisner KS, Strigari L, Konijnenberg M; EANM Dosimetry Committee. Re: Tumor Targeting and Three-Dimensional Voxel-Based Dosimetry to Predict Tumor Response, Toxicity, and Survival after Yttrium-90 Resin Microsphere Radioembolization in Hepatocellular Carcinoma. J Vasc Interv Radiol 2019;30:2047-8. [PMID: 31676203 DOI: 10.1016/j.jvir.2019.08.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
27 Allimant C, Deshayes E, Kafrouni M, Santoro L, de Verbizier D, Fourcade M, Cassinotto C, Hermida M, Guillot C, Mariano-Goulart D, Guiu B. Hepatobiliary Scintigraphy and Glass 90Y Radioembolization with Personalized Dosimetry: Dynamic Changes in Treated and Nontreated Liver. Diagnostics (Basel) 2021;11:931. [PMID: 34064296 DOI: 10.3390/diagnostics11060931] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Delicque J, Hermida M, Piron L, Allimant C, Belgour A, Pageaux GP, Ben Bouallegue F, Assenat E, Mariano-Goulart D, Guiu B, Cassinotto C. Intra arterial treatment of hepatocellular carcinoma: Comparison of MELD score variations between radio-embolization and chemo-embolization. Diagn Interv Imaging 2019;100:689-97. [PMID: 31281074 DOI: 10.1016/j.diii.2019.05.006] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]